St. Jude stock soared by up to 37% and shareholders will acquire $46.75 in cash and approx. 0.87 shares of Abbott common stock ($85 per share.)
Chairman and CEO of Abbott Laboratories Miles White expressed his excitement at the move suggesting it changes the companies medical device market contribution and strengthens its medical device presence and offering.
What impact do you see this having on the cardiovascular and wider medical technology market? Or even your career?
Nicola Lawler, Head of Marketing at Projectus Consulting